ABSTRACT
BACKGROUND: The Coxsackie- and Adenovirus Receptor (CAR) has been assigned two crucial attributes in carcinomas: (a) involvement in the regulation of growth and dissemination and (b) binding for potentially therapeutic adenoviruses. However, data on CAR expression in cancer types are conflicting and several entities have not been analysed to date. METHODS: The expression of CAR was assessed by immunohistochemical staining of tissue microarrays (TMA) containing 3714 specimens derived from 100 malignancies and from 273 normal control tissues. RESULTS: The expression of CAR was detected in all normal organs, except in the brain. Expression levels, however, displayed a broad range from being barely detectable (for example, in the thymus) to high abundance expression (for example, in the liver and gastric mucosa). In malignancies, a high degree of variability was notable also, ranging from significantly elevated CAR expression (for example, in early stages of malignant transformation and several tumours of the female reproductive system) to decreased CAR expression (for example, in colon and prostate cancer types). CONCLUSION: Our results provide a comprehensive insight into CAR expression in neoplasms and indicate that CAR may offer a valuable target for adenovirus-based therapy in a subset of carcinomas. Furthermore, these data suggest that CAR may contribute to carcinogenesis in an entity-dependent manner.
Subject(s)
Coxsackie and Adenovirus Receptor-Like Membrane Protein/metabolism , Neoplasms/metabolism , Adenoviridae Infections , Cell Transformation, Neoplastic/genetics , Coxsackievirus Infections , Gene Expression Regulation, Neoplastic , Humans , Protein Array AnalysisABSTRACT
Pseudoneoplastic regeneration has become an important differential diagnosis to gastric carcinoma. Increasing use of acetylsalicylic acid (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) appears to be related to this entity. In recent years knowledge of pseudoneoplastic regeneration has continuously improved and the proportion of this designation among cases sent to our institute for second opinion decreased from more than 50% in 2000 to approximately 10% today. In diagnostically difficult cases the gastritis status may help: the majority of patients with gastric carcinoma show either active or treated Helicobacter gastritis, whereas individuals with pseudocarcinomatous regeneration often show chemical reactive gastritis (reactive gastropathy). Gastric ulcers should always be followed-up during the healing phase. A second opinion may confirm the differential diagnosis.